Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

1391 ARTÍCULOS , VIENDO DEL 1111 AL 1125

Role of insulin resistance in Alzheimer's disease

Cai Z, Xiao M, Chang L, Yan LJ.

Metab Brain Dis. 2015 Aug;30(4):839-51. doi: 10.1007/s11011-014-9631-3. Epub 2014 Nov 16.

Tropisetron and its targets in Alzheimer's disease

Hashimoto K.

Expert Opin Ther Targets. 2015 Jan;19(1):1-5. doi: 10.1517/14728222.2014.983901. Epub 2014 Nov 15.

What are the Benefits of Exercise for Alzheimer's Disease? A Systematic Review of the Past 10 Years

Hernández SS, Sandreschi PF, da Silva FC, Arancibia BA, da Silva R, Gutierres PJ, Andrade A.

J Aging Phys Act. 2015 Oct;23(4):659-68. doi: 10.1123/japa.2014-0180. Epub 2014 Nov 21.

Using the Alzheimer's Association web site to improve knowledge of Alzheimer's disease in health care providers

Hughes ML, Lowe DA, Shine HE, Carpenter BD, Balsis S.

Am J Alzheimers Dis Other Demen. 2015 Feb;30(1):98-100. doi: 10.1177/1533317514559827. Epub 2014 Nov 25.

A computational method for computing an Alzheimer's disease progression score; experiments and validation with the ADNI data set

Jedynak BM, Liu B, Lang A, Gel Y, Prince JL; Alzheimer's Disease Neuroimaging Initiative.

Neurobiol Aging. 2015 Jan;36 Suppl 1:S178-84. doi: 10.1016/j.neurobiolaging.2014.03.043. Epub 2014 Oct 17.

Medical genetics-based drug repurposing for Alzheimer's disease

Zhang XZ, Quan Y, Tang GY.

Brain Res Bull. 2015 Jan;110:26-9. doi: 10.1016/j.brainresbull.2014.11.003. Epub 2014 Nov 22.

Improving the predictive value of interventional animal models data

Zeiss CJ.

Drug Discov Today. 2015 Apr;20(4):475-82. doi: 10.1016/j.drudis.2014.10.015. Epub 2014 Nov 4.

Roles and regulation of neutral sphingomyelinase-2 in cellular and pathological processes

Shamseddine AA, Airola MV, Hannun YA.

Adv Biol Regul. 2015 Jan;57:24-41. doi: 10.1016/j.jbior.2014.10.002. Epub 2014 Oct 27.

Configuration-specific immunotherapy targeting cis pThr231-Pro232 tau for Alzheimer disease

Wang JZ, Zhang Y.

J Neurol Sci. 2015 Jan 15;348(1-2):253-5. doi: 10.1016/j.jns.2014.11.011. Epub 2014 Nov 13.

Brain hypometabolism triggers PHF-like phosphorylation of tau, a major hallmark of Alzheimer's disease pathology

Arendt T, Stieler J, Holzer M.

J Neural Transm (Vienna). 2015 Apr;122(4):531-9. doi: 10.1007/s00702-014-1342-8. Epub 2014 Dec 6.

Pharmacotherapy of Alzheimer's disease: current and future trends

Geldenhuys WJ, Darvesh AS.

Expert Rev Neurother. 2015 Jan;15(1):3-5. doi: 10.1586/14737175.2015.990884. Epub 2014 Dec 8.

Tau aggregation and its interplay with amyloid-β

Nisbet RM, Polanco JC, Ittner LM, Götz J.

Acta Neuropathol. 2015 Feb;129(2):207-20. doi: 10.1007/s00401-014-1371-2. Epub 2014 Dec 10.

Pharmacological approaches for Alzheimer's disease: neurotransmitter as drug targets

Prakash A, Kalra J, Mani V, Ramasamy K, Majeed AB.

Expert Rev Neurother. 2015 Jan;15(1):53-71. doi: 10.1586/14737175.2015.988709. Epub 2014 Dec 12.

Safety and clinical effects of EVP-6124 in subjects with Alzheimer's disease currently or previously receiving an acetylcholinesterase inhibitor medication

Deardorff WJ, Shobassy A, Grossberg GT.

Expert Rev Neurother. 2015 Jan;15(1):7-17. doi: 10.1586/14737175.2015.995639. Epub 2014 Dec 15.

An alkaline phosphatase transport mechanism in the pathogenesis of Alzheimer's disease and neurodegeneration

Pike AF, Kramer NI, Blaauboer BJ, Seinen W, Brands R.

Chem Biol Interact. 2015 Jan 25;226:30-9. doi: 10.1016/j.cbi.2014.12.006. Epub 2014 Dec 11.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias